FDA Approves Gene Therapy for Ultra-Rare Immune Disease

Children with severe leukocyte adhesion deficiency type 1 can now access a life-saving treatment after years of waiting. The FDA approved Kresladi on Thursday, a one-time gene therapy developed by Rocket Pharma that helps kids fight off infections their bodies couldn't handle before.

LAD-1 is incredibly rare, affecting only about 1 in a million people worldwide. The disorder prevents white blood cells from working properly, leaving children vulnerable to deadly infections from everyday germs that most of us fight off without thinking twice.

Before this approval, the only real option was finding a matched sibling donor for a stem cell transplant. But most families don't have that option, leaving them with few places to turn when their children face repeated, life-threatening illnesses.

Rocket Pharma first submitted Kresladi for approval in 2024, but the FDA rejected it over concerns about how it was manufactured. The company went back, fixed the issues, and resubmitted, showing the kind of persistence that rare disease families know all too well.

The approval is limited to children who don't have a matched sibling donor available. That targeted approach means the therapy goes to the kids who need it most, when traditional treatments aren't an option.

With only about 25 new cases diagnosed each year, Kresladi won't be a blockbuster drug despite its multimillion-dollar price tag. But for the families facing this diagnosis, the numbers don't matter nearly as much as having a real chance at a healthy future.

The Ripple Effect

This approval adds to a growing wave of gene therapies reaching patients with ultra-rare diseases. Each success proves that even the smallest patient populations deserve innovation and investment, changing how we think about developing treatments when profits aren't the main driver.

The approval also shows how persistence pays off in rare disease research. Rocket didn't give up after the initial rejection, and families who've been waiting now have access to a treatment that could fundamentally change their children's lives.

Gene therapy continues to transform what's possible for diseases once considered untreatable. Every approval builds momentum for the next breakthrough, creating hope for other rare disease communities still waiting for their turn.

For families who've watched their children fight infections that most kids shake off in days, this approval means freedom from constant fear and hospital visits.